A detailed history of American International Group, Inc. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 14,352 shares of TARS stock, worth $395,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,352
Previous 14,263 0.62%
Holding current value
$395,397
Previous $288,000 80.9%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$19.61 - $39.22 $1,745 - $3,490
89 Added 0.62%
14,352 $521,000
Q4 2023

Feb 13, 2024

BUY
$12.98 - $20.73 $32,398 - $51,742
2,496 Added 21.21%
14,263 $288,000
Q3 2023

Nov 13, 2023

BUY
$14.75 - $24.62 $6,165 - $10,291
418 Added 3.68%
11,767 $209,000
Q2 2023

Aug 04, 2023

BUY
$11.57 - $19.63 $28,682 - $48,662
2,479 Added 27.95%
11,349 $205,000
Q1 2023

May 12, 2023

BUY
$11.92 - $16.27 $2,109 - $2,879
177 Added 2.04%
8,870 $111,000
Q4 2022

Feb 10, 2023

SELL
$14.12 - $18.72 $451 - $599
-32 Reduced 0.37%
8,693 $127,000
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $3,365 - $4,421
239 Added 2.82%
8,725 $149,000
Q2 2022

Aug 12, 2022

BUY
$11.08 - $19.08 $47,644 - $82,043
4,300 Added 102.72%
8,486 $124,000
Q1 2022

May 13, 2022

SELL
$14.49 - $24.28 $4,260 - $7,138
-294 Reduced 6.56%
4,186 $70,000
Q4 2021

Feb 11, 2022

SELL
$21.21 - $29.68 $2,842 - $3,977
-134 Reduced 2.9%
4,480 $101,000
Q3 2021

Nov 12, 2021

SELL
$21.45 - $29.22 $2,359 - $3,214
-110 Reduced 2.33%
4,614 $99,000
Q2 2021

Aug 13, 2021

BUY
$27.16 - $38.59 $29,821 - $42,371
1,098 Added 30.28%
4,724 $137,000
Q1 2021

May 07, 2021

BUY
$27.37 - $47.25 $1,423 - $2,457
52 Added 1.45%
3,626 $117,000
Q4 2020

Feb 12, 2021

BUY
$19.17 - $49.62 $68,513 - $177,341
3,574 New
3,574 $148,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $734M
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.